

Mitosis (MITO) is a liquidity protocol designed for the modular era that redefines cross-chain liquidity infrastructure. As a foundational DeFi protocol, Mitosis addresses the critical challenge of making cross-chain liquidity provisioning both attractive and accessible to liquidity providers.
By introducing liquidity to cross-chain LP positions, Mitosis enables liquidity providers to earn additional yield on their locked assets while maintaining flexibility through derivative tokens. This positions Mitosis as a key infrastructure layer in the evolving multi-chain DeFi ecosystem.
As of December 21, 2025, Mitosis maintains a market capitalization of approximately $14.73 million with 196.27 million tokens in circulation out of a total supply of 1 billion MITO tokens. The protocol supports an active community of 75,672 token holders across 17 exchange listings, demonstrating growing adoption in the cross-chain liquidity landscape.
Mitosis emerged from the recognition that cross-chain liquidity provisioning lacked flexibility and efficiency. While liquidity providers faced the challenge of having capital locked in isolated positions across different blockchain networks without generating additional returns beyond basic fee sharing, Mitosis introduced an innovative solution through its derivative token mechanism.
The protocol's inception reflects the broader industry shift toward modular blockchain architecture and the pressing need for seamless, capital-efficient cross-chain DeFi solutions. By enabling LPs to maintain liquidity while simultaneously participating in yield-generating opportunities across supported networks, Mitosis addresses a fundamental gap in the multi-chain infrastructure landscape.
Mitosis operates as a cross-chain liquidity protocol built on a foundation of several key innovations:
Mitosis operates as a decentralized protocol, removing intermediaries and centralized gatekeepers from cross-chain liquidity provisioning. By distributing operations across multiple blockchain networks and nodes, Mitosis ensures transparency, censorship resistance, and user sovereignty. This architecture empowers liquidity providers with direct control over their capital while maintaining the security guarantees provided by underlying blockchain networks.
The core innovation of Mitosis lies in its derivative token system. When liquidity providers deposit assets across chains, they receive corresponding derivative tokens that represent their locked positions. These derivative tokens operate on a 1:1 convertibility basis, ensuring that LPs can reclaim their original assets at any time while simultaneously utilizing these tokens to access additional DeFi opportunities.
This mechanism transforms previously illiquid LP positions into capital that can work across multiple protocols simultaneously, fundamentally changing the economics of cross-chain liquidity provision.
Mitosis maintains security across multiple blockchain networks through reliance on the underlying consensus mechanisms of supported chains. By operating on established platforms such as Ethereum L1 and L2 rollups, the protocol inherits the security properties and validation guarantees of these networks. This approach ensures that cross-chain transactions maintain cryptographic integrity and immutability through the combined validation power of multiple blockchain networks.
Mitosis enables LPs to generate yield through multiple pathways:
This multi-layered approach to yield generation creates a more attractive proposition for liquidity providers compared to traditional single-chain liquidity provision.
| Metric | Value |
|---|---|
| Current Price | $0.0750 |
| Market Capitalization | $14,726,369 |
| Fully Diluted Valuation | $75,030,000 |
| Circulating Supply | 196,273,082 MITO |
| Total Supply | 1,000,000,000 MITO |
| 24-Hour Trading Volume | $17,009.42 |
| Market Dominance | 0.0023% |
| Active Holders | 75,672 |
| Exchange Listings | 17 |
The protocol has experienced significant volatility since its all-time high, reflecting typical market dynamics during the development phase of emerging DeFi infrastructure. Current pricing represents a 83.34% discount from the peak valuation.
At approximately 19.63% of total supply currently in circulation, Mitosis maintains a substantial portion of tokens in reserve, indicating continued token release schedules aligned with protocol development milestones and ecosystem growth initiatives.
Mitosis operates on the BSC (Binance Smart Chain) network, utilizing the BEP-20 token standard. This selection provides access to a mature, widely-adopted blockchain ecosystem with established infrastructure for DeFi applications.
Contract Address (BSC): 0x8e1e6bf7e13c400269987b65ab2b5724b016caef
The protocol benefits from active open-source development efforts:
Mitosis (MITO) is available for trading across 17 cryptocurrency exchanges globally. For secure trading and access to MITO, users can trade on Gate.com, which provides comprehensive trading pairs, competitive fees, and advanced order types for MITO token transactions.
To learn more about purchasing MITO, visit our detailed How to Buy Mitosis Guide.
Mitosis represents an innovative approach to solving cross-chain liquidity challenges in the evolving DeFi landscape. Through its derivative token mechanism and multi-chain integration, the protocol enables liquidity providers to optimize capital efficiency while maintaining exposure to yield-generating opportunities across multiple blockchain networks.
While current market conditions reflect the broader cryptocurrency market volatility and the protocol's early development stage, Mitosis' technical innovation and strong community support position it as a noteworthy infrastructure layer for the modular blockchain era. Investors and users should conduct thorough due diligence and monitor protocol development progress as the ecosystem continues to evolve.
As of December 21, 2025, Mitosis (MITO) has a circulating supply of 196,273,082 tokens, with a total supply of 1,000,000,000 tokens. The token operates on a fixed supply model with no inflation mechanism, as the maximum supply equals the total supply, ensuring predictable tokenomics for long-term holders and the ecosystem.
MITO reached its all-time high of $0.45 on September 14, 2025, driven by market optimism surrounding the platform's cross-chain liquidity innovations and growing adoption of modular blockchain infrastructure.
Conversely, the token's lowest price was $0.05, recorded on October 10, 2025, reflecting broader market corrections and consolidation following the previous bull run.
As of the latest update on December 21, 2025, MITO is trading at $0.07503, representing a 1.14% increase over the past 24 hours. The token has experienced significant long-term volatility, declining 63.48% over the past year, though it shows resilience with recent daily gains.
Check current MITO market price
| Time Period | Change Percentage | Price Change |
|---|---|---|
| 1 Hour | +0.01% | +$0.000007502 |
| 24 Hours | +1.14% | +$0.000846 |
| 7 Days | +0.01% | +$0.000008 |
| 30 Days | -5.67% | -$0.004510 |
| 1 Year | -63.48% | -$0.130419 |
Mitosis is the liquidity protocol for the modular era that redefines cross-chain liquidity. The protocol makes cross-chain liquidity provision (LPing) more attractive by introducing liquidity to otherwise illiquid positions.
Mitosis LPs receive derivative tokens that maintain a 1:1 convertibility ratio with their locked assets. These derivative tokens enable liquidity providers to:
This innovative approach addresses a critical challenge in cross-chain DeFi by unlocking capital efficiency and reducing opportunity costs for liquidity providers.
Mitosis (MITO) is a liquidity protocol designed for the modular era that redefines cross-chain liquidity. As of December 21, 2025, MITO trades at $0.07503 with a 24-hour trading volume of $17,009.42. The token maintains a market capitalization of $14,726,369.34 with a fully diluted valuation of $75,030,000.
| Metric | Value |
|---|---|
| Current Price | $0.07503 |
| Market Cap | $14,726,369.34 |
| Fully Diluted Valuation | $75,030,000 |
| 24h Trading Volume | $17,009.42 |
| Circulating Supply | 196,273,082 MITO |
| Total Supply | 1,000,000,000 MITO |
| Market Rank | #984 |
| 24h Price Change | +1.14% |
Mitosis addresses a critical pain point in the DeFi ecosystem by making cross-chain liquidity provision more attractive and accessible. The protocol operates through a unique mechanism:
Derivative Token System: Mitosis LPs receive derivative tokens that maintain a 1:1 conversion ratio with their locked assets, providing immediate liquidity without compromising capital efficiency.
Multi-Chain DeFi Integration: LPs can deploy derivative tokens across supported Ethereum L1 chains and L2 rollups, enabling participation in various DeFi applications while maintaining exposure to their original cross-chain positions.
Yield Optimization: The protocol enables LPs to generate additional yield on top of default fee sharing, effectively allowing cross-chain assets to work across multiple earning opportunities simultaneously.
Cross-Chain Liquidity Provisioning: Mitosis revolutionizes how liquidity providers engage with cross-chain environments by eliminating the traditional trade-off between capital deployment and liquidity. This enables more efficient capital utilization across the modular blockchain ecosystem.
Mitosis is listed on 17 exchanges globally, with primary trading infrastructure on BSC (Binance Smart Chain). The token maintains active trading pairs and is accessible through major trading platforms including Gate.com, which provides comprehensive trading tools and market data for MITO.
Mitosis maintains an active community presence across multiple platforms:
The Mitosis community comprises liquidity providers, cross-chain DeFi users, and developers interested in modular blockchain infrastructure. Community discussions center on:
Access MITO through Gate.com and other supported exchanges. Gate.com provides comprehensive trading pairs, real-time market data, and secure trading infrastructure for purchasing MITO tokens.
Mitosis continues to position itself as a critical infrastructure layer for the modular blockchain era. The protocol's focus on solving cross-chain liquidity inefficiencies addresses a genuine market need as blockchain ecosystems become increasingly interconnected.
Mitosis represents an innovative approach to one of DeFi's most pressing challenges: efficient cross-chain liquidity provisioning. By enabling LPs to maintain liquidity while earning yield across multiple chains, the protocol addresses real market inefficiencies.
The project demonstrates:
However, investors should remain mindful of:
For participants interested in cross-chain DeFi infrastructure and liquidity optimization, Mitosis offers a compelling value proposition within the modular blockchain ecosystem. Whether monitoring as an investment opportunity or actively participating as a liquidity provider, Mitosis warrants attention as the blockchain landscape continues its modular evolution.
Last Updated: December 21, 2025
Data Source: Gate.com Market Data
MITO symptoms include muscle weakness, cramping, and pain. Common issues also involve swallowing difficulties, gastrointestinal problems, and hypotonia. Symptoms vary by individual severity.
Mito refers to mitochondrial disease, a group of genetic disorders where dysfunctional mitochondria cannot produce sufficient energy for cells. These conditions primarily affect the nervous system and muscles, causing severe health complications due to inadequate cellular energy production.
Mito derives from Italian, meaning 'myth' or 'legend'. In the crypto context, Mito represents a token symbolizing extraordinary vision and community-driven innovation within the Web3 ecosystem.
Life expectancy with mitochondrial disease varies widely depending on the specific type and severity, typically ranging from 30 to 60 years, which is significantly lower than the general population average.
Mitochondrial disease is diagnosed through genetic testing, clinical evaluation, and confirmatory tests including elevated creatine kinase and lactic acidosis levels. Genetic mutations serve as key diagnostic indicators.
Mitochondrial diseases result from mutations in mitochondrial or nuclear DNA. They are often hereditary, typically inherited maternally through mitochondrial DNA mutations. Inheritance risk depends on mutation type and the percentage of abnormal mitochondria present.
MITO disease currently has no cure. Treatment focuses on symptom management through physical therapy, hearing aids, and cochlear implants. Clinical trials are exploring emerging therapies to improve patient outcomes.











